| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA265382
Max Phase: Preclinical
Molecular Formula: C102H126N34O34
Molecular Weight: 2372.33
Molecule Type: Protein
Associated Items:
Representations
Canonical SMILES: Cc1cn([C@@H]2C[C@@H](C(=O)NCC(=O)O)N(C(=O)CNC(=O)[C@@H]3C[C@@H](n4cc(C)c(=O)[nH]c4=O)CN3C(=O)CNC(=O)[C@@H]3C[C@@H](n4cc(C)c(=O)[nH]c4=O)CN3C(=O)CNC(=O)[C@@H]3C[C@@H](n4cc(C)c(=O)[nH]c4=O)CN3C(=O)CNC(=O)[C@@H]3C[C@@H](n4cc(C)c(=O)[nH]c4=O)CN3C(=O)CNC(=O)[C@@H]3C[C@@H](n4cc(C)c(=O)[nH]c4=O)CN3C(=O)CNC(=O)[C@@H]3C[C@@H](n4cc(C)c(=O)[nH]c4=O)CN3C(=O)CNC(=O)[C@@H]3C[C@@H](n4cc(C)c(=O)[nH]c4=O)CN3C(=O)[C@@H](N)CCCCN)C2)c(=O)[nH]c1=O
Standard InChI: InChI=1S/C102H126N34O34/c1-45-29-121(95(163)113-78(45)146)53-13-62(86(154)106-22-71(138)131-39-55(123-31-47(3)80(148)115-97(123)165)15-64(131)88(156)108-24-73(140)133-41-57(125-33-49(5)82(150)117-99(125)167)17-66(133)90(158)110-26-75(142)135-43-59(19-68(135)92(160)112-28-77(144)145)127-35-51(7)84(152)119-101(127)169)129(37-53)70(137)21-105-87(155)63-14-54(122-30-46(2)79(147)114-96(122)164)38-130(63)72(139)23-107-89(157)65-16-56(124-32-48(4)81(149)116-98(124)166)40-132(65)74(141)25-109-91(159)67-18-58(126-34-50(6)83(151)118-100(126)168)42-134(67)76(143)27-111-93(161)69-20-60(128-36-52(8)85(153)120-102(128)170)44-136(69)94(162)61(104)11-9-10-12-103/h29-36,53-69H,9-28,37-44,103-104H2,1-8H3,(H,105,155)(H,106,154)(H,107,157)(H,108,156)(H,109,159)(H,110,158)(H,111,161)(H,112,160)(H,144,145)(H,113,146,163)(H,114,147,164)(H,115,148,165)(H,116,149,166)(H,117,150,167)(H,118,151,168)(H,119,152,169)(H,120,153,170)/t53-,54-,55-,56-,57-,58-,59-,60-,61+,62+,63+,64+,65+,66+,67+,68+,69+/m1/s1
Standard InChI Key: OLNUMYBKKMOUEN-YULBZLBTSA-N
Associated Targets(Human)
Granzyme K 19 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 2372.33 | Molecular Weight (Monoisotopic): 2370.9176 | AlogP: | #Rotatable Bonds: |
| Polar Surface Area: | Molecular Species: | HBA: | HBD: |
| #RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
| Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
References
| 1. Jordan S, Schwemler C, Kosch W, Kretschmer A, Schwenner E, Stropp U, Mielke B. (1997) Synthesis of new building blocks for peptide nucleic acids containing monomers with variations in the backbone, 7 (6): [10.1016/S0960-894X(97)00079-6] |
Source
Source(1):